Member Info for JimiHendrix

I do understand, there are usually sales people focused on different products and markets. Business Development Specialist is a fancy title for salesman… I know many.

Does anybody have a copy of the job descriptions for the sales people from before Christmas? I can’t remember if they specifically mentioned Covid or AIHL.

Something concerning me a bit. Re. The business development specialist job advertised for a few days ago with a focus on selling the covid POC test.

Do people think the existing sales team has been focusing on AIHL and only now are they looking for someone to work on covid test sales?

I know the POC test has been given out to interested parties for review over the past couple of months. It just makes me wonder if maybe they’ve not started full time sales with this yet and have been hoping something comes from the interested parties.

Still alot of unknowns with regard to the BA.2 variant spreading like wild-fire in Scandinavia, and beginning to here and elsewhere aswell now.

BA.2 infection after Omicron seen in Norway...
Anders Fomsgaard, who is chief physician and virus researcher at the Statens Serum Institut (SSI), told Danish media that a few cases have been seen in Norway where people who have been infected with Omikron have subsequently been infected with BA.2.

He reportedly called it “remarkable” that Omicron and BA.2 have significant differences when it comes to immunity and infection.

Allan Randrup, professor of experimental virology at the University of Copenhagen, said however that “so far we have not seen any variants of covid-19 that have not had any cross-immunity at all, and that immunity after infection is usually good."

“The system will be high-armed when you have just overcome an infection,” said Randrup.

Viggo Andreasen, who is a professor of mathematical epidemiology at Roskilde University, explained in various media that other viruses that circulate between people can infect people every few years, “this also applies to the flu,” he stressed.

Covid vaccines should still be effective, however, one of the reasons for BA.2’s rapid spread may be that it is more resistant to people’s immunity, “which allows the variant to infect better,” Fomsgaard reportedly said.

You certainly still seem to be interested Lloyd! :)

Actually Genedrive is interested in the UK market for the COV19-ID POC test, it was the PCR test that they were not interested in the UK. They said they are targetting Europe first, whilst the test awaits CTDA approval (which will likely be very soon).

Testing is far from dead! There's a lot of people trying to talk this down at the moment to help them get the ultimate low buy in price.

General outlook is highly positive for POC testing in the UK... this gives an idea for how the NHS use POC tests here...

Point of Care Testing (PoCT) are tests that because of modern technology can be performed nearer to the patient, for example on a ward/clinic, in a GP surgery, or by district nurses in the patient’s home. All grades or professions can be involved in PoCT.

Point of Care devices are currently being used across South Tees Hospitals NHS Foundation Trust in a variety of settings from emergency medicine to acute care to helping speed up the diagnostic process often streamlining treatment putting patients on the correct treatment pathway.

The term Point of Care Testing (PoCT) is a term people will be hearing more frequently as new technologies and development of new PoCT is on-going at a rapid pace, and is a significant growth area in modern pathology.

Dr Long, flu is sometimes tested for and sometimes just a verbal diagnosis is given by a GP based on symptoms. My point is that won’t be possible anymore because flu often presents similar symptoms to covid. So POC testing will need to be done to confirm what it is, quickly and accurately.

Even if Covid becomes more seasonal they will still need to test in order to differentiate between covid and flu. Sometimes flu is diagnosed simply based on symptoms however this won’t be the case going forward, testing will be needed to check whether it’s covid. And of course generally testing will continue for years in order to keep track and monitor the virus.

Yes, the shareprice wasn't sustainable in the 60's without sales/order/partner news – that was definitely the time to be selling if you want to trade it. Now though, at 20p you'd be mad to sell (unless you have to) as imo this presents a pretty fantastic opportunity to buy before the inevitable rise begins again... and it will. I think with sentiment so low, any positive sales news... even a tiny order will send the shareprice up at least 50-100% from here. Any substantial orders could take it back to 80p again where it touched less than 2 months, that's 300% from the current price.

The POC test is a different market to the mass-testing focused LFT and PCR tests and should see plenty of demand for years even when demand for LFT and PCR testing calms down. At the moment the focus with testing is about quantity rather than quality, that will change once the virus poses less of a threat. Genedrive's has the best POC test out there, and I think they'll do very well with it. There really aren't many competitors yet either.

When you look at the current low mcap and how much cash they have, and with both the Covid POC and AIHL tests launching as we speak, along with a new dedicated sales team on the case... it all starts to look quite exciting!

He’s set up an in-house sales team who will handle the direct sales now. He’s making good decisions imo, I’m expecting much more commercial progress now with full time sales focused team.

Expecting news of POC distibution deal/sales order and also first AIHL sales over the next few weeks and 50-70p. Just a bit of patience needed!

*almost certainly

Europe could easily order PCR tests from Genedrive, if they are short of tests (they are) and Sysmex can manufacture them (they can) then why would they not be interested in buying from Genedrive? The only reason we had trouble selling in Europe was because suppliers had already established relationships… now however if they are unable to supplier they will undoubtedly be looking for new suppliers.

Maybe there is some life left in our high quality PCR test after all! Either way we will almost have news regarding POC test distribution deal and orders very soon.

Those 2x 2m trades are almost certainly share transfers, hence why the 2nd trade was at a slightly higher price. If they were sells then the second would have been the same it more likely lower.

This is actually interesting, they’ve been approached recently by institutional investors looking to participate in a placing.

Q32: Have you received any interest from institutional investors?

In recent months, a number of institutions have expressed an interest in investing in the Company. We work with finnCap to attract additional Institutional Investors, although it would be unusual for an Institutional Investor to build a position through simply purchasing stock in the market when there were no large lines of stock available to buy from existing institutional investors. In most cases this would mean that they only way to attract Institutional support would be through a Placing.

Useful to know that what happens is they will experience the feeling of surprise lol.

Q14: Do you see Dam’s orders increasing is size after the initial £750k and do you have a model for that increase for professional use and self test

The initial order was just that, an initial order, and given the volume of testing that is done in their clinics by the estimation we would expect further follow-on orders. As to the scale and frequency of these orders we have no guidance to provide – it will be driven by demand and our contract has no minimum orders.

Q22: The recent DAM health agreement is great news, and great to get an initial order. When will this 1st order be delivered and is this a monthly volume? Whats the forecast volume per week for this contract?

This was an initial stocking order and we have no guidance for the scale and frequency of forthcoming orders – it will be driven by demand but there is a minimum monthly order quantity (undisclosed) within the contract. In our announcement of 1 November, we stated that DAM Health is currently using approximately 200,000 in-clinic COVID tests per month.

Yes I’m anticipating this too. Following that, I expect distribution agreements will be announced for COVID-ID very shortly, with initial orders.

Good news, should see an uplift today and this week without their drag in the share price. Institutional’s have to sell some when the share price has risen by certain amount in order to balance their portfolio, it has nothing to do with their view on future share price. Looking back through their TR1’s it’s worth noting the share price has usually risen when they have announced they’ve sold some.